BioSig Technologies, Inc. Selects Access Strategy Partners to Accelerate Commercial Sales
Leading healthcare management firm to enhance the Company’s market access strategy as it expands the installation base of its signal...
Year: 2021
Syneos Health Releases 2022 Health Trends
New Era of Biopharma Product Development to be Fueled by Value Creation, Human Centricity and Industry ChangeMORRISVILLE, N.C., Dec. 21,...
Optimi Health Receives Dealers License Inspection and Introduces Quality Assurance Department
VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or...
Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents
VANCOUVER, British Columbia, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed...
Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on...
Predictive Oncology – Year-end Shareholder Update!
EAGAN, Minn., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology, (POAI), a knowledge-driven company focused on applying artificial intelligence (AI)...
Pliant Therapeutics to Participate in the 40th Annual J.P. Morgan Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company...
ExCellThera announces settlement of its patent infringement claims against Selleck Chemicals
MONTRÉAL, Dec. 21, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering...
Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom
-- Expanding Pasithea Clinics footprint in London --MIAMI BEACH, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ:...
Certara Announces FDA Renewal and Expansion of Certara’s Biosimulation Software for Reviewing Regulatory Submissions
FDA holds more than 400 Simcyp™ and Phoenix™ software licenses across 12 divisions and officesPRINCETON, N.J., Dec. 21, 2021 (GLOBE...
Montreal company gives $250K to fight ovarian cancer
Blachford is supporting Dr. Lucy Gilbert and the DOvEE project through the creation of the Blachford Ovarian Cancer Research Award...
Allarity Therapeutics Closes Its Recapitalization, Share Exchange, and $20M PIPE Investment; Lists on U.S. Nasdaq Stock Market
Press release Cambridge, MA U.S.A. (December 21, 2021) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”), a...
Zogenix Submits New Drug Application for FINTEPLA® (Fenfluramine) in Japan for the Treatment of Epileptic Seizures Associated with Dravet Syndrome
EMERYVILLE, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company specializing in rare disease therapies, announced that...
Galectin Therapeutics Announces Closing of $10 Million in Debt Financing from Its Chairman, Richard E. Uihlein
NORCROSS, Ga., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin...
Achilles Therapeutics to present at the 40th Annual J.P. Morgan Healthcare Conference
LONDON, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell...
First U.S. patients with persistent cardiac arrythmias treated using Volta Medical’s artificial intelligence-based analysis
Novel, FDA-cleared and CE-certified medical device is designed to help cardiologists identify cardiac abnormalities in patients undergoing ablation treatment for...
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
- New IND Expands Liver Disease Pipeline for CRV431 - - IND Clearance Allows CRV431 to Move Directly into Phase...
TFF Pharmaceuticals Announces Final Data from Phase 1b Study of Inhaled Voriconazole Powder in Asthma Patients
Final Safety and Pharmacokinetic Data Continue to Support Progression to Phase 2 in the Near Term for Treatment of Invasive...
Biomea Fusion to Present at the 40th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated...
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022
- Finalizing Two-Dose Study Design for Phase 2 Trial of ADVM-022 in Wet AMDwith Intention to Dose First Patient in...
